OMICS Publishing Group, Journal of Bioequivalence & Bioavailability provides an immediate Open Access to its content making research freely available to the public which supports a greater global exchange of knowledge in the chemical and pharmacological areas.
2. About The journal
Started Year: 2009
Frequency: Bimonthly Journal
Indexed in ISI Thompson Reuters & Scopus
Index Copernicus Value: 5.24
Strength of Editorial board: 80
Total No. of Articles Published: 145
Total 4 Volumes and 30 issues
Special Issues: 12 accepted
3. George Perry
Dean and Professor
College of Sciences
University of Texas
at San Antonio
USA
4. Journal of Bioequivalence & Bioavailability:
an Open Access journal for scientists and by
scientists. The idea to launch this project
stemmed from the widespread opinion that
scientists want other scientists to have full
control of the peer-review process.
JBB aims to provide a scholastic platform
for researchers and academia to share
innovations, theory and practices of
various research fields of Pharmacy and
Chemistry. The importance will be on
publishing quality papers rapidly and
5. Journal of Bioequivalence & Bioavailability is an
Open Access online journal, which publishes
research articles, reviews, letters and guest edited
single topic issues, in all areas of Bioequivalence
and Bioavailability. Topics covered in this
interdisciplinary journal include: Bioavailability,
Bioequivalence, and Drug Product Selection,
Biowaivers, and Biosimilars, Bioavailability of
Pharmaceuticals and Other Supplements, Oral
Bioavailability, BA/BE of Novel Drug Delivery
Systems, etc.
The Journal of Bioequivalence & Bioavailability
(JBB), an online open-access journal of the
OMICS Group and the premier journal for
Bioequivalence and Bioavailability education
research, has been selected for indexing by
6. Classification No. of Manuscripts Received
Bioequivalence 58
Bioequivalence Strategies in 4
Development
Bioavailability 34
Pharmacokinetics 16
Drug Development & Bioanalytical 11
Methodologies
Comparative Bioavailability Generic 4
Drug Products (ANDA):
Bioequivalence Studies
In Vivo/In Vitro Methods to Determine 4
Bioavailability
Pharmaceutical Technology, Clinical 6
9. 4th World Congress on Bioavailability
and Bioequivalence: Pharmaceutical R
& D Summit during May 20-22, 2013 at
DoubleTree by Hilton Beijing, China.